- Least squares mean (±SE).
- Day -7 means are arithmetic mean values.
- Statistically significant (P<0.0001) compared to placebo.
Success with CYTOPOINT treatment
Success across patient types
No significant differences in success with CYTOPOINT for3:
This was a randomized, placebo-controlled, masked laboratory study in 40 laboratory Beagles. Dogs were randomly allocated within batch and block to receive on Day 0 by subcutaneous injection with either placebo (n=20) or CYTOPOINT® at 2.0 mg/kg (n=20). Pruritus was induced in all dogs on study Days -7(±2), 1, and 28(±1) by intravenous (IV) challenge with IL-31 (2.5μg/kg). Pruritus scores were measured by a masked observer for 120 minutes following administration of IL-31; specifically, at consecutive 1-minute intervals, “yes”/”no” decisions were made in regards to whether a pruritic behavior was displayed by each dog within the 120-minute observation period, resulting in a maximum possible total score of 120.
A single 2.0 mg/kg dose of CYTOPOINT® (n=50) or placebo (n=52) was administered subcutaneously on Day 0 in this randomized, double-blind, placebo-controlled study of dogs diagnosed with atopic dermatitis. The primary effectiveness endpoints were treatment success in pruritus as assessed by owners on a VAS (success defined as a ≥20 mm reduction in pruritus scores compared to Day 0) and by investigators with CADESl-03 (success defined as a ≥50% decrease in CADESl-03 score compared to Day 0).1
This study was an independent, real-world, retrospective analysis of medical records of dogs with allergic dermatitis treated with CYTOPOINT® from November 2015 to October 2016. Treatment success for owner-assessed pruritus was empirically defined as a ≥2 cm reduction in Pruritus Visual Analog Scale (PVAS) from baseline. The 135 dogs in this study included 80 with atopic dermatitis (7—seasonal, 73—non-seasonal), 10 with concurrent food allergy and atopic dermatitis, 45 with atopic dermatitis of undetermined cause, 3 lost to follow-up and 0 flea allergic dogs (this study was completed in Fort Collins, Colorado).
For animals. For health. For you.
This site is intended for U.S. Animal Healthcare Professionals.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2019 Zoetis Services LLC. All rights reserved.